John F. Heerdink, Jr., Author at Vista Partners LLC

Join The Tribe Public CEO Series: “Sabotage or Success: Discover How Your Mind Awaits Your Orders” – (Oct. 1, 2025 – 11:30am ET)

by John F. Heerdink, Jr. September 30, 2025 90Views 0Likes

Tribe Public extends its appreciation to members who have already registered for this week’s CEO Presentation and Q&A Webinar, scheduled for Wednesday, October 1, at 8:30 a.m. PT / 11:30 a.m. ET. The session, titled “Sabotage or Success: Discover How Your Mind Awaits…

Eupraxia’s Diffusphere Tech Driving Growth And Interest: EOE Clinical Milestone and Big Public Offering

by John F. Heerdink, Jr. September 30, 2025 100Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX) reported robust clinical results in its highest-dose cohort—8mg per injection—within the ongoing RESOLVE Phase 2b trial for patients with eosinophilic esophagitis (EoE). The pronounced tissue health improvements and eosinophil reduction in Cohort 9 prompted company advisors and safety…

Modular Medical Secures $4.4M Seeking to Fast-Track FDA Clearance and Launch Pivot Insulin Patch Pump -( $MODD $LLY $TNDM $MDT )

by John F. Heerdink, Jr. September 29, 2025 89Views 0Likes

Modular Medical (NASDAQ: MODD) has made a flurry of strategic moves and operational strides in recent weeks as it works to reshape the landscape of insulin delivery for millions living with diabetes. The company secured approximately $4.4 million in gross proceeds through…

Jennifer Garner’s Once Upon a Farm Files for NYSE IPO: Transforming Kids’ Nutrition with Farm-Fresh Values – ( $OFRM $GS $JPM $BAC )

by John F. Heerdink, Jr. September 29, 2025 127Views 0Likes

Once Upon a Farm, the organic baby and kids’ food pioneer co-founded by actress Jennifer Garner, officially filed for an initial public offering on the New York Stock Exchange this week, signaling a remarkable milestone for a brand that has fused celebrity…

Serina Therapeutics CEO: Why Now Is the Time to Invest in Biotech – ( $SER $IBB $XBI )

by John F. Heerdink, Jr. September 26, 2025 99Views 0Likes

In a video released this week, Serina Therapeutics' (NYSE American: SER) Chief Executive Officer Steven Ledger outlined what he described as a rare convergence of factors for biotech investing, highlighting both daunting market conditions and an emerging window of opportunity. Watch Now…

Palsonify FDA Greenlight: Crinetics Seeks to Launch Oral Therapy for Acromegaly Patients – ( $CRNX $IBB $XBI )

by John F. Heerdink, Jr. September 26, 2025 89Views 0Likes

San Diego, CA based Crinetics Pharmaceuticals (CRNX) delivered a watershed moment on Friday as the FDA granted approval of Palsonify (paltusotine), the first once-daily, oral therapy for acromegaly—a rare hormonal disorder—propelling shares to their strongest session of the year. On Friday, Crinetics…

Cantor Fitzgerald Analyst Report Drives Biotech Buzz About Eupraxia After Major Funding – ( $EPRX $IBB $XBI )

by John F. Heerdink, Jr. September 25, 2025 91Views 0Likes

Cantor Fitzgerald has recently updated their coverage of Eupraxia Pharmaceuticals (NASDAQ: EPRX) with an “Overweight” rating and an $11 target price—a move that places the emerging biotech on the radar of institutional investors seeking innovation in the field of locally delivered, extended-release…

Opendoor’s Stock Soars 330%: Inside the Meme-Fueled Turnaround and CEO Shakeup – ( $OPEN $CVNA $SHOP )

by John F. Heerdink, Jr. September 24, 2025 87Views 0Likes

Opendoor Technologies (NASDAQ: OPEN) has staged one of the year's more improbable turnarounds on Wall Street, propelled as much by operational pivots as by waves of speculative investor fervor. Once flirting with delisting, the online real estate platform recently notched a one-year…

uniQure Stock Soars 196% on Huntington’s Disease Gene Therapy Potential Breakthrough – ( $QURE $IBB $XBI )

by John F. Heerdink, Jr. September 24, 2025 97Views 0Likes

uniQure (NASDAQ: QURE) electrified Wall Street this week, with shares surging nearly 200% after the company reportedly announced transformative clinical data for its Huntington’s disease gene therapy, AMT-130. The biotech, which just secured up to $175 million in non-dilutive funding, is riding…

Eupraxia Pharmaceuticals Seeks To Propel Biotech Innovation With $70 Million Funding, EoE Trial Advances – ( $EPRX $IBB $XBI )

by John F. Heerdink, Jr. September 23, 2025 97Views 0Likes

Eupraxia Pharmaceuticals (NASDAQ: EPRX), a clinical-stage biotechnology company developing targeted therapies that leverage a proprietary extended-release delivery system to provide the right dose of a drug, in the right place, for the right amount of time, has recently become a headline act…

Author page: John F. Heerdink, Jr.

Join The Tribe Public CEO Series: “Sabotage or Success: Discover How Your Mind Awaits Your Orders” – (Oct. 1, 2025 – 11:30am ET)

Eupraxia’s Diffusphere Tech Driving Growth And Interest: EOE Clinical Milestone and Big Public Offering

Modular Medical Secures $4.4M Seeking to Fast-Track FDA Clearance and Launch Pivot Insulin Patch Pump -( $MODD $LLY $TNDM $MDT )

Jennifer Garner’s Once Upon a Farm Files for NYSE IPO: Transforming Kids’ Nutrition with Farm-Fresh Values – ( $OFRM $GS $JPM $BAC )

Serina Therapeutics CEO: Why Now Is the Time to Invest in Biotech – ( $SER $IBB $XBI )

Palsonify FDA Greenlight: Crinetics Seeks to Launch Oral Therapy for Acromegaly Patients – ( $CRNX $IBB $XBI )

Cantor Fitzgerald Analyst Report Drives Biotech Buzz About Eupraxia After Major Funding – ( $EPRX $IBB $XBI )

Opendoor’s Stock Soars 330%: Inside the Meme-Fueled Turnaround and CEO Shakeup – ( $OPEN $CVNA $SHOP )

uniQure Stock Soars 196% on Huntington’s Disease Gene Therapy Potential Breakthrough – ( $QURE $IBB $XBI )

Eupraxia Pharmaceuticals Seeks To Propel Biotech Innovation With $70 Million Funding, EoE Trial Advances – ( $EPRX $IBB $XBI )

Your Guide To Staying Informed In The Markets